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Taking inspiration from Ctr-1 Mets7 Cu(I) binding motif, effective 
hybrid catalysts have been developed for asymmetric Henry 
condensation under green conditions. The introduction of an 
unnatural dipeptide mimic allowed to increase the catalytic 
performance. Metal transporters’ binding domains could be 
exploited as strategy for designing hybrid catalysts for 
homogeneus catalysis. 
Hybrid catalyst attracted the attention of several research 
groups in the last years.1-3 The development of a hybrid 
catalyst involves the synergic combination of a 
biomacromolecular scaffold such as a protein, and an active 
catalytic moiety such as a transition metal complex.4 The so 
obtained artificial metalloenzymes have indeed shown high 
selectivity in the synthesis of enantiomerically enriched 
compounds in aqueous media.5, 6 These successful stories have 
been possible thanks to the intimate knowledge of both the 
protein scaffold that hosts the metal entity and of the 
interaction(s) between the metal and its chelating ligands (the 
first sphere of coordination), as well as with the protein 
environment (the second sphere of coordination). 
Nevertheless, the use of modified protein scaffolds requires 
studies of site-direct mutagenesis and molecular biology 
techniques.7 The use of small peptides capable of binding 
transition metals could be thus a much more convenient 
approach thanks to the easiness and modularity of their 
synthesis. On the other hand, reproducing the functional 
groups’ spatial arrangement of a catalytic site with small 
peptides is still a challenge.8-10 Metal transporters are 
proteins11, 12 devoted to the trafficking of ions across the 
membranes and contain peptide domains able to bind metal 
ions.13-18 A powerful approach to design hybrid metal-peptide 
catalysts could thus take advantage of the modulation of their 
binding activity. The native amino acid sequence of the binding 
domains could be optimized by inserting appropriate 
functional amino acids.19-22 In this way it could be possible to 
increase the ability to form the complex with the metal. 
Furthermore, the introduction of unnatural amino acids and of 
molecular scaffolds could stabilize specific conformations of 
the peptide, creating the molecular architecture of a catalytic 
site.23-25  
It has been established that copper binding sites in proteins 
are normally dominated by histidine, cysteine and methionine 
residues.26, 27 The main differences among them are that 
methionine does not form cross linking or bridge two metal 
ions and does not contain a protonable side chain. The 
thioether indeed is a functional group that does not have a pH 
dependency, and is less prone to oxidation. Human Ctr-1 (hCtr-
1) is a glycosylated membrane protein of 190 amino acids, 
belonging to the highly conserved family of copper 
transporters.8 This domain is particularly important in defining 
the pore’s dimensions and controlling Cu(I) trafficking across 
the membrane bilayer. It stands out for the presence of 
methionine (Met)-rich regions arranged as MXXM or MXM 
motifs containing three to five methionine residues. Starting 
from the sequence of the Met-rich motif present in the N-
terminal domain of yeast yCtr1, Arnesano and co-workers 
designed a 8-mer sequence (MTGMKGMS), called Mets7, 
particularly able in binding Cu(I) and Pt(II) drug complexes.28, 29 
Circular dichroism studies indicated that Mets7 tends to adopt 
a random-coil structure in aqueous solution, while, upon 
coordination with Cu(I), it undergoes a large conformational 
change obtaining two consecutive β-turns. 
The aim of our work has been the preliminary evaluation of 
Mets7, and a small library of its derivatives, as chiral ligands of 
Cu(I) to be used in homogenous catalysis. We hypothesized 
that Mets7 could favor Cu(I) coordination environments 
avoiding the redox cycling of copper between Cu(I) and 
Cu(II).30, 31 This feature is particularly profitable in view of using 
this system as catalyst preserving the metal centre. 
Furthermore, the stable conformation of the peptide upon 
Cu(I) complexation could influence enantioselectivity in 
asymmetric reactions. To the best of our knowledge Mets7, as 
well as to other metal binding domains from metal 
transporters, has been never used as ligands for asymmetric 
homogenous catalysis. 
As the model reaction to test our hypothesis, we selected the 
Henry condensation.32-35 This reaction is an important 
synthetic tool to form a C–C bond, widely used for the 
obtainment of β-hydroxy nitro derivatives. Henry 
condensation is normally base-catalyzed, leading to side 
reactions such as the Cannizzaro aldehyde disproportionation 
or water elimination of the product. Due to the low 
enantioselectivity evinced under aqueous or green-solvent 
conditions, it’s clear the necessity of exploring new types of 
environmentally friendly base-free catalysts.36, 37  
Table 1. Amino acid sequence modifications starting from Mets7 sequence and 
molecular structure of unnatural scaffold X 
Peptide Sequence 
Mets7 M  T  G  M  K  G  M  S 
A K  G  K  P  G  M  S 
B K  G  M  P  G  M  S 
B1 K  T  G  M  P  G  M  S 
C M  G  K  P  G  M  S 
S1 M  T  G  M  (X) M  S 
 
 Starting from Mets7 sequence, we modified the number and 
the position of methionine residues (Table 1). Met position 
could vary the coordination geometry of Cu(I) complex, from 
linear to trigonal planar or tetrahedral. We expected that the 
so obtained peptides could assume different ordered or 
unordered secondary structures upon coordination with Cu(I), 
thus affecting the ability to induce chirality in the 
corresponding hybrid catalysts. Furthermore, the synthesis of 
peptide mimetic S1 containing the unnatural scaffold X  was 
also planned with the idea of stabilizing the turn conformation. 
Indeed, compound X is a easily accessible delta amino acid 
able to stabilize β-structures when inserted in model 
peptides.38, 39  
To support this hypothesis, we performed REMD calculations 
to compare the conformational behavior of metal-free Mets7 
and S1.40 Simulations were conducted as suggested by a recent 
article where several methods were compared for their ability 
to predict the native conformations of peptides (see ESI for 
details).41 The room temperature trajectories of Mets7 and S1 
were analyzed by clustering, H-bonds and other geometrical 
analyses. Data obtained from the cluster analysis are 
summarized in Table 2, while representative conformations of 
clusters #1 and #2 of peptide S1 are shown in Figure 1.  
As expected, the replacement of KG with scaffold X reduces 
the conformational freedom of peptide S1, if compared to 
Mets7. Indeed, only two principal conformations are predicted 
by cluster analysis for the former peptide (clusters #1 and #2, 
with a percentage population (pop%) of 49 and 42%, 
respectively), principally differing in the orientation of the N-
terminal segment (residues M1-M4) due to the rotation of the 
amidic bond linking M4 to scaffold X. 
Table 2. Resultsa from the Cluster Analysis of the 75-100 ns Section of the 302.8 K 
REMD Trajectory for Mets7 and S1. 
 Mets7 S1 
# pop% ψ,φ avgb pop% ψ,φ avgb 
1 29.8 13.6±55.5,  
-98.8±29.3 
49.0 67.1±157.7,  
-54.8±62.0 
2 27.5 103.4±65.1,  
-91.3±80.7 
42.0 119.2±121.0,  
-55.0±64.9 
3 19.0 38.0±117.8,  
-88.9±23.2 
8.0 43.0±154.8,  
-60.1±57.2 
4 15.6 12.5±66.5,  
-40.3±84.2 
0.9 -10.0±171.2,  
-67.5±67.4 
5 8.1 35.7±62.6,  
-35.6±83.3 
0.1 74.0±159.5,  
-16.7±97.5 
[a]The full set of dihedrals is reported in Table TS1, ESI while representative 
geometries are depicted in Figure FS1, ESI. [b]Average ψ and φ dihedrals (deg.) 
and corresponding standard deviations are obtained for each cluster 
representative structure by averaging the corresponding values for all residues, 
without the capping Ac and NH2 groups. 
Moreover, the ψ and φ dihedrals of representative geometries 
of both clusters #1 and #2 of S1 are compatible with a turn-like 
conformation, even if H-bond analysis did not show any of the 
hydrogen bonds typical of a β-turn (Table TS2, ESI). Conversely, 
four similarly populated clusters are obtained from the 
analysis of the Mets7 trajectory, suggesting a conformational 
freedom which is compatible with an intrinsically disordered 
peptide. Finally, the distances between the three methionine 
sulfur atoms of Mets7 and S1 (d1, d2 and d3, Figure 1) were 
found to be generally larger for the former (d1 = 9.5±3.0 Å, d2 
= 12.7±4.3 Å, d3 = 10.9±3.1 Å) than for the latter peptide (d1 = 
9.8±1.6 Å, d2 = 9.3±3.2 Å, d3 = 7.7±2.0 Å) in the respective 
REMD trajectories, suggesting that complexation of copper 
should be favored for S1. 
 
 
 
 
 
 
 
 
 
  
Figure 1. Representative conformations of clusters #1 and #2 as obtained from 
cluster analysis of the 302.8 K REMD trajectory of peptide S1. Non-standard 
dihedrals of the dipeptide mimetic X are marked with an asterisk.  
All the peptides were prepared by solid phase synthesis using 
the Fmoc strategy (see ESI).42 Cu(I) complexes were prepared 
by mixing equimolar amounts of peptide with copper(II) 
acetate in methanol. Two equimolar amounts of ascorbic acid 
were added to reduce Cu(II) to Cu(I). This methodology was 
applied taking into consideration that Cu(I) is sensitive to air 
oxidation until stabilized upon coordination. The ESI-MS 
spectra (Figure FS8-13, ESI) showed the formation of 
complexes for all the screened peptide ligands. Furthermore, 
only the mononuclear [Cu(pep)]+ complex was evinced. In 
order to exclude any unspecific binding event, an Ala-scan 
sequence ATGAKGAS, in which the three methionines were 
replaced by alanine, was also prepared. The ESI-MS analysis 
showed that no interaction occurred (Figure FS14, ESI), 
indicating that the binding under the same analysis conditions 
is solely due to the presence of the coordinating sulphur of 
methionine.29  
The conformational behavior of compounds A, B, B1, C and S1 
and their complexes was investigated in water. As expected, 
the CD spectra of A, B, B1, C alone were characterized by the 
presence of a negative band at 195 nm, indicating the absence 
of a preferred conformation (Figure FS15, ESI). NMR 
experiments on peptide mimic S1 indicated that it is present in 
solution as a mixture of cis/trans rotamers of the tertiary 
amide on the piperidine ring, confirming the molecular 
modelling hypothesis. Furthermore, a turn conformation of 
the unnatural scaffold X was also observed (see ESI for details). 
CD spectra of Cu(I) complexes confirmed in all cases the 
binding with the metal (Figure 2), as evinced by the increase of 
the intensity of the negative band below 195 nm.31 
Furthermore, only for Mets7 and S1 complexes, a blue shift of 
this band was observed, indicating the presence of a stable 
beta-turn conformation upon complexation. These data 
indicated that the MXXMXXM binding motif is necessary to 
obtain an ordered secondary structure in the presence of Cu(I). 
On the contrary, the bidentate motif (MXXM in peptides B and 
B1, and MXXXXM in peptide C) is not sufficient for stabilizing 
the molecular architecture of the complex. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CD spectra of Cu(I) peptide complex 
The catalytic performance of peptide-Cu(I)-complexes was 
thus investigated in the asymmetric nitro-aldol Henry 
condensation under green conditions. 43  
Benzaldehyde, 4-NO2- and 4-Cl-benzaldehyde were selected as 
model substrates in a preliminary screening using 
nitromethane both as co-substrate and co-solvent. Firstly, 
different solvents (water, 2-propanol, methanol and t-BuOH) 
and different temperature values (10, 25 and 40 °C) were 
evaluated (see table TS3 in SI). In particular, we decided to 
screen solvents that, based on recent solvent selection rules,44, 
45 are considered preferable for working in green conditions. 
The reactions were thus carried out using t-BuOH for avoiding 
the competitive spontaneous condensation reaction observed 
to take place with the other screened solvents. Furthermore, t-
BuOH was able to completely dissolve the peptide complexes, 
allowing to use them in catalytic amount. Moreover, no base 
was added and the temperature was maintained at 40 °C to 
increase the reaction rate without harming the 
enantioselectivity. 
Table 3. Henry reaction catalyzed by peptide ligand-Cu(I) complexes 
 
 
 
 
 
Entry Peptide Substrate C (%)[a] e.e. (%)[b] TON 
1 Mets7 R = H 54 48 (R) 12 
2 Mets7 R = 4-NO2  90 46 (S) 20 
3 Mets7 R = 4-Cl  65 rac 14 
4 A R = H - - - 
5 A R = 4-NO2  - - - 
6 A R = 4-Cl  10 rac 2 
7 B R = H 10 22 (S) 2 
8 B R = 4-NO2  25 7 (R) 6 
9 B R = 4-Cl  15 9 (R) 3 
10 B1 R = H 10 5 (R) 2 
11 B1 R = 4-NO2 20 rac 4 
12 B1 R = 4-Cl 10 rac 2 
13 C R = H 20 24 (S) 4 
14 C R = 4-NO2  50 rac 11 
15 C R = 4-Cl  20 18 (R) 4 
16 S1 R = H 50 75 (R) 11 
17 S1 R = 4-NO2  62 40 (S) 14 
18 S1 R = 4-Cl-  54 rac 12 
All reactions were carried out for 12 h using 5 mol % complex in t-
BuOH:CH3NO2=50:50 (2 mL) [a]Conversion (C) was obtained by 1H-NMR analysis. 
[b]Data were compared by taking the average of three independent experiments. 
Enantiomeric excess was determined using HPLC equipped with chiral OD-H 
column. Eluent: hexane/2-propanol=90/10 flow=1.0 mL/min, λ = 215 nm or 
hexane/2-propanol=80/20 flow=0.5 mL/min, λ = 254 nm. [sub]f = 10 mM, [cat]f = 
0.45 mM. 
As reported in Table 3, only the catalytic complex with the 
monocoordinating peptide A, resulted inactive or less active as 
catalyst (entries 4-6). In all the other cases, the reaction was 
found effective especially using Mets7 and S1 complexes 
(entries 1, 2, 16, 17). In the case of Mets7 complex the yield 
was up to 90 % within 12 h (entry 2). For this reason this was 
the reaction time set for the evaluation of catalyst 
performance (TON).  
Regarding the enantiomeric excess, using 4-Cl-benzaldehyde 
as the substrate, only a racemic mixture was obtained (entries 
3, 6, 9, 12 and 18). As an exception, a 18 % e.e. in favor of R 
configuration was obtained when peptide C was employed. In 
the case of benzaldehyde and 4-NO2-benzaldehyde, different 
enantioselectivities were observed depending on the catalyst 
geometry. Indeed, low enantioselectivity was obtained by 
using B, B1 and C complexes that would lead to a bidentate 
complex and in which the peptides do not assume a stable β-
turn conformation (entries 7-15). This behavior might depend 
on the higher molecular mobility of these complexes making 
them capable to accommodate different labile geometries. As 
evinced by using peptide B or C-copper(I) complexes the 
condensation product was obtained in S configuration for 
benzaldehyde while the other enantiomer was achieved for 
both 4-NO2 and 4-Cl-benzaldehyde.  
This inversion of product configuration might be due to the 
MXXM (peptide B) or MXXXXM (peptide C) motifs causing a 
different chirality arrangement around the metal (entries 7-9 
and 13-15).On the other hand, Mets7 and S1 beta-turn 
complexes, gave the R isomer as the main enantiomer with 
good e.e. in the condensation reaction of benzaldehyde 
(entries 1 and 16) whereas when starting from 4-NO2-
benzaldehyde the reaction led to the S enantiomer (entries 2 
and 17).  
From these results, it is evident that the presence of a stable 
beta-turn conformation is crucial for enhancing both the 
reaction rate and the enantioselection. This ordered 
conformation could influence the coordination arrangement 
(Cu(S-Met)3) playing thus an important role on the stabilization 
of the reduction potential of the metal centre. This feature is 
indeed critical for avoiding redox cycling between copper(I) to 
copper(II). In this way, the catalytically active form of the 
complex results much more stabilized, and thus functional to 
carry out the condensation reaction. Indeed, Mets7 and S1 
peptides probably act as catalytic pocket creating a second 
coordination sphere arrangement. The chemical fine-tuning of 
the catalytic moiety results adjusted in a localization of the 
substrate inside the mimicking “funnel-shape cavity” of the 
 peptide influencing the enantioselectivity and consequently 
the absolute configuration of the products 
In conclusion, we designed and prepared modified peptide 
sequences inspired to Ctr1 Mets7 copper binding motif. These 
compounds were able to bind copper(I) and they were 
preliminarily tested as hybrid catalysts in asymmetric Henry 
condensation under green reaction conditions. The 
introduction of the unnatural scaffold X, able to stabilize the 
geometry and the conformation of the complex, allowed to 
obtain good e.e. and yield when benzaldehyde and 4-NO2-
benzaldehyde were used as the substrates. We can thus 
conclude that the use of modified metal binding protein 
domains from metal transporters can be a valuable strategy 
for designing hybrid catalysts for homogeneous asymmetric 
reactions. 
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